Strumento inattivo

Altre lingue Teva Pharmaceutical Industries Limited Other OTC

Azioni

TEVJF

IL0006290147

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...	14/06
Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	14/06
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	04/06
Teva Pharmaceuticals - New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY Extended-Release Injectable Suspension from Invega Sustenna	03/06
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)	01/06
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024	01/06
Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill	30/05
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)	30/05
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day)	30/05
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.	22/05
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	21/05
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	21/05
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S	21/05
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	17/05
New EVP, Teva Global Operations appointed	16/05
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	15/05
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations	15/05
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024	15/05
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	09/05
En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...	09/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

Teva Pharmaceutical Industries Limited: costretta a ulteriori cessioni

01 febbraio 2024 alle 17:43

Il CEO di Teva sul secondo trimestre e sul potenziale accordo con il Dipartimento di Giustizia degli Stati Uniti

02 agosto 2023 alle 21:19